PM2.5 and PM>2.5 were separately collected in Kanazawa, Japan in every season from the spring of 2017 to the winter of 2018, and nine polycyclic aromatic hydrocarbons (PAHs) and six nitropolycyclic aromatic hydrocarbons (NPAHs) were determined by HPLC with fluorescence and chemiluminescence detections, respectively. Atmospheric concentrations of both PAHs and NPAHs showed seasonal changes (highest in the winter and lowest in the summer), which were different from the variations of TSP and PM2.5 (highest in the spring). Contributions of major sources to combustion-derived particulate (Pc) in PM2.5 were calculated by the NP-method using pyrene and 1-nitropyrene as representative markers of PAHs and NPAHs, respectively. The annual average concentration of Pc accounted for only 2.1% of PM2.5, but showed the same seasonal variation as PAHs. The sources of Pc were automobiles (31%) and coal heating facilities/industries (69%). The source of Pyr was almost entirely coal heating facilities/industries (98%). A backward trajectory analysis showed that automobile-derived Pc was mainly from Kanazawa and its surroundings and that coal heating facilities-derived Pc was transported from city areas in central and northern China in the winter and during the Asian dust event in the spring. These results show that large amounts of PAHs were long-range transported from China in the winter. Even in spring when the coal heating season was over in China, PAHs came over to Japan after Asian dust storms passed through Chinese city areas. The main contributor of NPAHs was automobiles in Kanazawa and its surroundings. The recent Pc concentrations were much lower than those in 1999. This decrease was mostly attributed to the decrease in the contribution of automobiles. Thus, changes of atmospheric concentrations of Pc, PAHs and NPAHs in Kanazawa were strongly affected not only by the local emissions but also long-range transport from China.

(1)Background：To date, no studies have epidemiologically examined whether the concentration of particulate matter (PM) 2.5 and its ionic components is related to the prevalence of skin symptoms. Therefore, this study aimed to clarify this association in patients with allergic diseases. (2)Methods: From February 1 to May 31, 2020, we evaluated the daily prevalence of skin symptoms in outpatients with allergic diseases being treated at Fukuoka Hospital, Fukuoka, Japan, and measured the concentration of PM2.5 and its ionic components. （3）Results: Univariate analysis showed a statistically significant association between skin symptoms and the concentration of PM2.5 and the ionic components SO42-, NH4+, K+, and Mg2+, and multivariate analysis showed a statistically significant association between the daily prevalence of skin symptoms and the concentration of the ionic components SO42- or Mg2+. (4)Conclusions: Our findings indicate that the concentration of some PM2.5 ionic components may affect skin symptoms in patients with allergic diseases.

High-grade gliomas present a significant challenge in neuro-oncology because of their aggressive nature and resistance to current therapies. Boron neutron capture therapy (BNCT) is a potential treatment method; however, the boron carrier compounds used — such as 4-borono-L-phenylalanine (L-BPA) — have limitations. This study evaluated the use of boron-conjugated 4-iodophenylbutanamide (BC-IP), a novel boron compound in BNCT, for the treatment of glioma. Using in vitro drug exposure experiments and in vivo studies, we compared BC-IP and BPA, with a focus on boron uptake and retention characteristics. The results showed that although BC-IP had a lower boron uptake than BPA, it exhibited superior retention. Furthermore, despite lower boron accumulation in tumors, BC-IP showed significant survival improvement in glioma-bearing rats compared to controls. These results suggest that BC-IP, with its unique properties, may be an alternative boron carrier for BNCT. Further research is required to optimize this potential treatment modality, which could significantly contribute to advancing the treatment of high-grade gliomas.